Cartesian Therapeutics Announces Landmark Study in The Lancet Neurology of First Successful Clinical Trial of RNA Cell Therapy in Autoimmunity

Cartesian Therapeutics has announced the success of a clinical trial for RNA cell therapy in autoimmunity. The study, published in The Lancet Neurology, used rCAR-T therapy to treat patients with myasthenia gravis and demonstrated long-lasting clinical improvement without toxicities. This is the first successful Phase 2 trial using an engineered cell therapy to treat autoimmunity, and it may be ..